Advanced NSCLC Targeted Therapy - EGFR

Sort by:
Relevance Thumbs Up Comments Views Newest Oldest
19:01

Insights from ELCC 2025

ELCC 2025 Summary: Overcoming Primary Resistance to NSCLC Immunotherapy

FEATURING Roberto Ferrara
  • 1 view
  • April 17, 2025
32:06

Insights from ELCC 2025

ELCC 2025 Summary: Monday Morning Practice - MARIPOSA Highlights & Frontline Advanced EGFRm NSCLC Management

FEATURING Balazs Halmos
  • 8 views
  • April 15, 2025
  • 1
10:07

Catherine Shu

Managing Cutaneous Toxicities in EGFRm NSCLC: Insights From Amivantamab Use

  • 2 views
  • April 15, 2025
04:54

Insights from ELCC 2025

ELCC 2025 Summary: Highlights From the Recent Advanced NSCLC Trials - MARIPOSA, COCOON, SOHO-01, & KROCUS

FEATURING Bjørn Henning Grønberg
  • 18 views
  • April 14, 2025
  • 1
03:01

ecancer

ELCC 2025 Summary: Preventing Moderate to Severe Dermatologic AEs in 1L EGFRm Advanced NSCLC Treated With Amivantamab + Lazertinib

FEATURING Nicolas Girard
  • 8 views
  • April 11, 2025
10:01

Insights from ELCC 2025

ELCC 2025 Insights: Osimertinib After Definitive CRT for Unresectable Stage 3 EGFRm NSCLC - Updated OS Analysis From the LAURA Study

FEATURING Sara Ramella
  • 17 views
  • April 9, 2025
16:41

Insights from ELCC 2025

ELCC 2025 Summary: Targeted Treatment of RAS-Mutant NSCLC: Adagrasib + Pembro or Fulzerasib + Cetuximab for 1L KRAS G12C; Daraxonrasib Monotherapy for 2L+ Pan-RAS G12X-Cm+ Disease

FEATURING Joop Langen
  • 9 views
  • April 9, 2025
05:35

COR2ED The Heart of Medical Education

ELCC 2025 Summary: EGFRm and HER2-Mutated/Overexpressing Advanced NSCLC Updates From Recent Trials

FEATURING Nicolas Girard
  • 31 views
  • April 2, 2025
21:58

GRACE

Reading a Molecular Testing Report in Lung Cancer

FEATURING Karen Yun
  • 35 views
  • April 1, 2025
  • 1
13:49

GRACE

EGFR and HER2 Targeted Therapies in NSCLC: New Developments and a Changing Landscape

FEATURING Xiuning Le
  • 30 views
  • April 1, 2025
13:11

Mor Moskovitz

Subcutaneous Amivantamab for EGFR+ mNSCLC

  • 12 views
  • March 13, 2025
09:48

Mor Moskovitz

PALOMA 1 & 2 Trials: Subcutaneous Amivantamab in Combination With Lazertinib in Patients With EGFRm NSCLC

  • 1 view
  • March 13, 2025
14:08

Mor Moskovitz

PALOMA-3 Study: Subcutaneous vs. Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFRm NSCLC

  • 4 views
  • March 13, 2025
14:28

OncoAlert

Early Stage NSCLC: Adjuvant & Neoadjuvant Chemo + IO, Adjuvant Alectinib, Osimertinib After CRT in Stage 3 Disease

FEATURING Gilberto Lopes
  • 29 views
  • March 13, 2025
  • 2
16:26

OncoAlert

Updates in NSCLC: Top Trial Highlights From 2024 (LAURA, CROWN, REACH PC, and MARIPOSA-2)

FEATURING Charu Aggarwal
  • 25 views
  • March 13, 2025
  • 1
04:13

Total Health

91 y/o Female With EGFR M+ NSCLC With Liver Metastasis: Panel Discussion

FEATURING Ramakrishna Battini, Fred Hirsch, David Carbone, Holger Gieschen, Jason Porter
  • 4 views
  • March 13, 2025
05:05

Total Health

EGFRm NSCLC Development Strategy and Overview

FEATURING Fred Hirsch
  • 7 views
  • March 8, 2025
06:57

Total Health

Advances in EGFRm NSCLC & New Treatment Paradigms

FEATURING Fred Hirsch
  • 39 views
  • March 8, 2025
10:02

Manmeet Ahluwalia

Identifying Patients With EGFR-Mutant mNSCLC Who May Require Treatment Intensification

  • 15 views
  • March 4, 2025
08:52

Won Jin Jeon

Exploring the Time Toxicity of Frontline Regimens for Treatment of EGFR-Mutated NSCLC

  • 16 views
  • March 4, 2025
  • 1
06:14

GRACE

EGFR-Mutated Lung Cancer Combination Therapies

FEATURING Julia Rotow
  • 35 views
  • February 28, 2025
04:13

GRACE

Treatment Options for EGFRm NSCLC: Osimertinib Monotherapy

FEATURING Julia Rotow
  • 17 views
  • February 28, 2025
03:25

GRACE

Treatment Options for EGFRm NSCLC: Osimertinib + Chemo (FLAURA2 Trial)

FEATURING Julia Rotow
  • 21 views
  • February 28, 2025
06:28

GRACE

EGFR-Mutated Lung Cancer: CNS Metastases Co-Mutations & Treatment

FEATURING Ibiayi Dagogo-Jack, Julia Rotow, Misty Shields, Alissa Cooper, Angel Qin
  • 116 views
  • February 28, 2025
07:19

GRACE

Targeted Therapies for NSCLC: Overview & Surgically Resected Disease

FEATURING Angel Qin
  • 17 views
  • February 28, 2025

Advanced NSCLC Targeted Therapy - EGFR

No subtopics